StocksFin Logo
Evotec SE country of incorporation
|
|
4,715 employees
NASDAQ | Healthcare | Drug Manufacturers—Specialty & Generic
Apellis Pharmaceuticals, Inc. country of incorporation
|
|
DR. Cedric Francois
|
476 employees
NASDAQ | Healthcare | Biotechnology
Q322 reported Sep 30, 2022 Reporting Period
$173.88M 8.9% vs. Q321 Revenues Q322
16.34% -39.5% vs. Q321 Gross Profit Margin
-27.19% ! -132.3% vs. Q321 Net Profit Margin
-79.81M ! -483.8% vs. Q321 Free Cash Flow Q322
$-0.14 ! -132.9% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Q322 reported Nov 7, 2022 Reporting Period
$22.06M 290.4% vs. Q321 Revenues Q322
93.74% -3.7% vs. Q321 Gross Profit Margin
-867.2% ! 13.3% vs. Q321 Net Profit Margin
-154.61M ! 8.3% vs. Q321 Free Cash Flow Q322
$-1.75 ! 23.2% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Loading...
Loading...
Ratios
As of
Dec 31, 2022
Sep 30, 2022
Quick Ratio
2.92
6.21
Current Ratio
3.18
7.21
Cash Ratio
1.23
5.06
Price to Book
2.25
24.25
Price to Sales
3.55
100
Price to Earnings
-15.19
-9.74